Barrett Bready is back on the program. He’s the CEO of Nabsys, a company with some new technology for genome mapping. Originally Nabsys had been working to develop nanopore sequencing, but after a recent reboot has become focused on scaling up scientists' ability to read structural genomic information. Barrett compares Nabsys’ new multiplex technology for genome mapping to the improvement of arrays over single nucleotide (SNP) detection.
Will This New Nano Technology Be the Microarray of Genomic Structural Variation? Barrett Bready, Nabsys
www.mendelspod.com
Mendelspod Podcast
Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine.
Offering a front row seat to the Century of Biology, veteran podcast host Theral Timpson interviews the who's who in genomics and genomic medicine.Listen on
Substack App
RSS Feed
Appears in episode
Theral Timpson
Recent Episodes
Will This New Nano Technology Be the Microarray of Genomic Structural Variation? Barrett Bready, Nabsys